
Quarterly report 2026-Q1
added 05-08-2026
Avenue Therapeutics Net Debt 2011-2026 | ATXI
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Avenue Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | -3.13 K | -8.74 M | -2.67 M | -11.8 M | 5.68 M | 3.85 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.68 M | -11.8 M | -2.28 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
-16.8 M | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
-7.39 M | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
71 K | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Autolus Therapeutics plc
AUTL
|
-32.7 M | $ 1.7 | 3.03 % | $ 452 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
BioNTech SE
BNTX
|
-7.45 B | $ 92.14 | 1.33 % | $ 22.3 B | ||
|
AstraZeneca PLC
AZN
|
-3.91 B | - | - | $ 96.9 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Athira Pharma
ATHA
|
-68.5 M | - | - | $ 269 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
52 M | - | 0.74 % | $ 768 M | ||
|
Abcam plc
ABCM
|
15.3 M | - | - | $ 4.9 B | ||
|
Galera Therapeutics
GRTX
|
-17 M | - | -32.59 % | $ 7.61 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Affimed N.V.
AFMD
|
-31.3 M | - | -34.95 % | $ 21.5 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Checkmate Pharmaceuticals
CMPI
|
-12.1 M | - | - | $ 231 M | ||
|
Celyad Oncology SA
CYAD
|
-12.2 M | - | - | $ 12.5 M | ||
|
Berkeley Lights
BLI
|
-60.5 M | - | -7.31 % | $ 87 M | ||
|
Generation Bio Co.
GBIO
|
17.3 M | - | - | $ 344 M | ||
|
IMV
IMV
|
-19.8 M | - | - | $ 13.1 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
-3.5 M | - | -4.36 % | $ 27 M | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
-41.4 M | - | - | $ 384 M | ||
|
Gracell Biotechnologies
GRCL
|
-1.39 B | - | - | $ 3.37 B | ||
|
Compugen Ltd.
CGEN
|
-87.6 M | $ 2.8 | 7.28 % | $ 262 M | ||
|
Anika Therapeutics
ANIK
|
-31.2 M | $ 14.88 | -0.93 % | $ 213 M | ||
|
Coherus BioSciences
CHRS
|
-85.6 M | $ 1.61 | 2.55 % | $ 189 M | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
-5.16 M | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-5.46 M | $ 3.4 | -1.16 % | $ 5.6 M | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | ||
|
Albireo Pharma
ALBO
|
-236 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
-96.6 M | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
65.3 M | $ 20.86 | -0.71 % | $ 2.65 B | ||
|
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B |